Why do we lack an effective vaccine against herpes simplex virus infections?
- 1 July 2000
- journal article
- review article
- Published by Elsevier in Microbes and Infection
- Vol. 2 (8) , 973-978
- https://doi.org/10.1016/s1286-4579(00)00339-7
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- Herpes Simplex Virus Type 1 Infection of Activated Cytotoxic T CellsThe Journal of Experimental Medicine, 1999
- Initial and innate responses to viral infections — pattern setting in immunity or diseaseCurrent Opinion in Microbiology, 1999
- Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes.Journal of Clinical Investigation, 1998
- Immunization with a Lymphocytic Choriomeningitis Virus Peptide Mixed with Heat Shock Protein 70 Results in Protective Antiviral Immunity and Specific Cytotoxic T LymphocytesThe Journal of Experimental Medicine, 1998
- DNA vaccines for the prophylaxis and modulation of HSV infectionsExpert Opinion on Investigational Drugs, 1998
- To kill or to cure: options in host defense against viral infectionCurrent Opinion in Immunology, 1996
- Lymphocyte responses and cytokinesCell, 1994
- Passive immunization protects the mouse eye from damage after herpes simplex virus infection by limiting spread of virus in the nervous systemJournal of General Virology, 1990
- Evolution of recurrent herpes simplex lesions. An immunohistologic study.Journal of Clinical Investigation, 1985
- Glycoprotein C of herpes simplex virus 1 acts as a receptor for the C3b complement component on infected cellsNature, 1984